Compare Recursion Pharmaceuticals Inc (RXRX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs TeraWulf Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while TeraWulf Inc trades at $19.93 (market cap $9.35B). The key difference: TeraWulf Inc is far larger — about 6.1× Recursion Pharmaceuticals Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | WULF | |
|---|---|---|
Market Cap | $1.53B | $9.35B |
Sector | Health | Technology |
52-Week High | $6.79 | $28.98 |
52-Week Low | $2.84 | $4.76 |
Enterprise Value | $946.50M | $12.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
TeraWulf (WULF) trades at $18.86, up 3.85% today, amid volatile AI infrastructure sector movements. The stock shows bearish technical signals with negative earnings trends, having missed Q1-Q3 2025-2026 EPS estimates. Fundamentally, the company reported a net loss of $661.42M on $168.46M revenue in 2025, though it secured a significant 20-year, $19B deal with Anthropic for AI data center capacity.
Despite unanimous analyst buy ratings and a $37.22 consensus price target suggesting 97% upside, WULF faces execution risks from high cash burn and negative margins. The Anthropic partnership offers long-term revenue potential but requires substantial capital investment amid competitive and regulatory pressures in the AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
